Latest Hi-Tech Pharmacal Co. (HITK) Headlines Hi-Tech

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Hi-Tech Pharmacal Co. (HITK) Headlines

Hi-Tech Pharmacal Reports Sales of $59.9 Million for the Third Quarter Ended January 31, 2014
Business Wire - Tue Mar 11, 6:00AM CDT
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results for the third fiscal quarter ended January 31, 2014.

Hi-Tech Pharmacal Has Returned 28.2% Since SmarTrend Recommendation (HITK)
Comtex SmarTrend(R) - Thu Mar 06, 11:06AM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 9 months, Hi-Tech Pharmacal has returned 28.22% as of today's recent price of $43.30.

Akorn Guidance Worries Street As Strategy Hits Delays
at Investor's Business Daily - Mon Mar 03, 4:30PM CST
Specialty drugmaker Akorn's Q4 earnings met estimates Monday, but its 2014 guidance and a new accounting problem halted the IBD 50 stock dead in its tracks. Akorn (AKRX) said profit totaled 14 cents a share, up a penny from the year-earlier quarter...

Akorn Q4 Meets But Guidance Disappoints, Stock Down
at Investor's Business Daily - Mon Mar 03, 9:07AM CST
Specialty drugmaker Akorn (AKRX) Monday reported a Q4 in line with estimates, but it guided 2014 below expectations and shares plummeted 15% in early trading in the stock market today. The company said profit totaled 14 cents a share, up a penny from...

Hi-Tech Pharmacal Shares Up 28.4% Since SmarTrend's Buy Recommendation (HITK)
Comtex SmarTrend(R) - Thu Feb 27, 9:43AM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 8 months, Hi-Tech Pharmacal has returned 28.40% as of today's recent price of $43.36.

Youngevity International (YGYI) Inks Consulting Agreement with Creative Memories Co-Founder Rhonda Kanning Anderson
Business Wire - Wed Feb 26, 7:05AM CST
Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com), a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels, announced today that Rhonda Kanning Anderson will immediately begin advising the company on expanding its product offering in Scrap Books, Photo Albums, and Memory Books in both the digital and paper formats. Rhonda will have a keen focus on helping build the Heritage Makers Brand in the area of digital scrap booking as well as assist in the development and marketing of more traditionally oriented products for this space.

Hi-Tech Pharmacal Up 28.3% Since SmarTrend Uptrend Call (HITK)
Comtex SmarTrend(R) - Wed Feb 12, 4:51PM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 8 months, Hi-Tech Pharmacal has returned 28.28% as of today's recent price of $43.32.

Actavis, Valeant, Jazz: New Roles For Specialty Pharma
at Investor's Business Daily - Fri Feb 07, 1:12PM CST
Last month, during an otherwise ho-hum conference call on 2014 financial guidance, Valeant Pharmaceuticals CEO Michael Pearson electrified the stock market by making an audacious promise. "Today we're introducing our sixth strategic initiative, which...

Hi-Tech Pharmacal awarded US FDA's approval for Bromfenac Ophthalmic Solution
M2 - Fri Jan 24, 4:40AM CST
US-based specialist pharmaceuticals company Hi-Tech Pharmacal Co Inc (NasdaqGS:HITK) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) final approval for its Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day).

Hi-Tech Pharmacal Receives Final Approval for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day)
Business Wire - Thu Jan 23, 6:00AM CST
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted final approval for the Company's Abbreviated New Drug Application, (ANDA) for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday (R) ophthalmic solution, 0.09%. The product is used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Hi-Tech plans to launch the product immediately.

Fish & Richardson Wins Patent Infringement Suit for Allergan Over Generic LUMIGAN® 0.01%
PR Newswire - Wed Jan 15, 3:50PM CST
Fish & Richardson announced today that it won an important Hatch-Waxman litigation for client Allergan, Inc. (NYSE: AGN) in a patent infringement suit against Sandoz Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Hi-Tech Pharmacal Co., Inc., Watson Laboratories, Inc., Watson Pharmaceuticals, Inc., and Watson Pharma, Inc. On January 14, 2014, the U.S. District Court for the Eastern District of Texas ruled that the defendants could not sell their generic versions of Allergan's popular LUMIGAN® (bimatoprost ophthalmic solution) 0.01% until Allergan's last patent expires in 2027.

Hi-Tech Pharmacal in $25M Medicaid settlement
AP - Thu Dec 26, 10:06AM CST
NEW YORK (AP) — Hi-Tech Pharmacal said Thursday that it will pay $25 million to resolve allegations that it overcharged the Texas Medicaid program.

Hi-Tech Pharmacal Co. (HITK) Stock Research Links

HITK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 158

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 153

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 119

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 183

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 203

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 211

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 138

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 365

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 139

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading

Top 5 Most Recently Viewed Articles

BlueLinx Expands Its Reach with New Portland Distribution Hub

Updated Category News Views 147

BlueLinx Unveils New Distribution Center in Portland BlueLinx Holdings Inc. (NYSE: BXC) has officially opened a greenfield distribution center in Portland, enhancing its operational footprint in the Pacific Northwest. This facility is a significant addition to the company’s distribution capabilities, as it strategically positions BlueLinx to serve the growing demands of...

Continue Reading
IBA Partners with China Gold to Advance X-ray Technological Growth

Updated Category News Views 255

Strategic Partnership for Industry Advancement In a significant move for the irradiation processing industry, IBA (Ion Beam Applications S.A., EURONEXT) has joined forces with China Gold Irradiation (CGI), the premier irradiation service provider in China. This collaboration is set to elevate the standards of irradiation services by incorporating advanced X-ray...

Continue Reading
Amerant Bank and Partners Generate Support for Local Charity

Updated Category News Views 189

Generous Collaboration: Amerant Bank's Community Impact In a heartwarming display of community spirit, Amerant Bank has partnered with Sedano’s Supermarkets and Fresco y Más to make a significant difference in the lives of underserved children and families. The culmination of their efforts was marked by a grand check presentation to Centro Mater, a renowned...

Continue Reading
Mediar Therapeutics Advances Phase 2 Trial for Rare Lung Disease

Updated Category News Views 123

Mediar Therapeutics Initiates Phase 2 WISPer Trial Mediar Therapeutics, Inc., a pioneering clinical-stage biotechnology company, has reached a major milestone by dosing the first patient in its Phase 2 WISPer clinical trial. This trial focuses on evaluating MTX-463, a first-in-class therapy designed to combat idiopathic pulmonary fibrosis (IPF). The primary goal of this...

Continue Reading
Chime Biologics and Waterstone Unite for ADC Innovation

Updated Category News Views 242

Chime Biologics and Waterstone Forge a New Path in ADC Development Chime Biologics and Waterstone Pharmaceuticals have officially announced a strategic partnership designed to enhance the capabilities and efficiencies within the Antibody-Drug Conjugate (ADC) industry. By combining their expertise, both companies aim to provide integrated services that boost the...

Continue Reading